Novel SERD Reduces Risk of Death by 30% in HR+ Breast Cancer

Patients who received elacestrant demonstrated a clinically meaningful improvement in progression-free survival as compared to those who received standard of care.

Related Keywords

Boston ,Massachusetts ,United States ,Dallas ,Texas ,New Jersey ,New Brunswick ,Aditya Bardia ,Carlos Arteaga ,Rutgers Robert Wood Johnson Medical School ,Ut Southwestern Medical Center ,Menarini Group Radius Health ,Rutgers Cancer Institute Of New Jersey ,Cancer Center ,Harvard Medical School ,Simmons Comprehensive Cancer Center ,San Antonio Breast Cancer Symposium ,Menarini Group ,Radius Health ,Mass General Cancer Center ,Medical Center ,Medscape Medical ,Rutgers Cancer Institute ,Breast Cancer ,Alignant Breast Neoplasm ,Cancer ,Alignant Neoplasia ,Arcinoma ,Breast ,Metastatic Breast Carcinoma ,Chemotherapy ,Neoplasm ,Tumor ,Endocrine Therapy ,Hormone Therapy ,Arm ,Fatigue ,Antiretroviral Therapy ,Antiretroviral Therapy Art ,Art ,Atazanavir ,Darunavir ,Travirine ,Ipranavir ,Herapy Antiretroviral ,Hiv Infection ,Shiv ,Nucleoside Reverse Transcriptase Inhibitors ,Ucleoside Analo ,